These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Goa KL; Barradell LB; Plosker GL Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820 [TBL] [Abstract][Full Text] [Related]
13. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. Katsiki N; Tentolouris N; Mikhailidis DP Curr Opin Cardiol; 2017 Jul; 32(4):422-429. PubMed ID: 28362666 [TBL] [Abstract][Full Text] [Related]
15. Sugar and fat, a recipe for disaster. New guidelines for the pharmacological management of diabetic dyslipidaemia. Tallis GA; Beng C; Popplewell P; Phillips P Aust Fam Physician; 1995 Sep; 24(9):1638-9, 1642-7, 1649. PubMed ID: 7487649 [TBL] [Abstract][Full Text] [Related]
16. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. Al-Bahrani AI; Bakhiet CS; Bayoumi RA; Al-Yahyaee SA Diabetes Res Clin Pract; 2005 Jul; 69(1):44-51. PubMed ID: 15904989 [TBL] [Abstract][Full Text] [Related]
17. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Keating GM; Ormrod D Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067 [TBL] [Abstract][Full Text] [Related]
18. Management of dyslipidemia in adults with diabetes. Haffner SM Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988 [TBL] [Abstract][Full Text] [Related]
19. Lipid disorders in NIDDM: implications for treatment. Taskinen MR; Smith U J Intern Med; 1998 Nov; 244(5):361-70. PubMed ID: 9845851 [TBL] [Abstract][Full Text] [Related]
20. Study of changes in antioxidant enzymes status in diabetic post menopausal group of women suffering from cardiovascular complications. Kumawat M; Sharma TK; Singh N; Ghalaut VS; Vardey SK; Sinha M; Kaushik GG Clin Lab; 2012; 58(3-4):203-7. PubMed ID: 22582492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]